🇮🇪Ireland
16°C Partly Cloudy · Dublin
Live Updates
--:--:-- IST
Writer Login
Latest
Clinical Trials in the USA / NCT07742878
Recruiting Observational

An Early Prospective Study of the Traq™ Device for Characterization of Binocular Ocular Function in Normal Subjects and Subjects With Recent Traumatic Brain Injury

NCT07742878 · tracked via the Priya Life Science USA tracker
Sponsor
Rebiscan, Inc.
Phase
Observational
Started
2026-07-14
Last updated
2026-08-03

Condition(s) studied

Mild Traumatic Brain Injury, ConcussionBinocular Visual FunctionNeuro-OphthalmologySaccadic Eye Movements

Investigational drug(s) / intervention(s)

Binocular ophthalmic neurodiagnostic device

Binocular ophthalmic neurodiagnostic device: Participants will undergo non-invasive binocular ophthalmic neurodiagnostic measurements and ocular assessments. No treatment or intervention will be administered as part of the study.

Study summary

The early prospective study of Traq™ (an investigational binocular ophthalmic neurodiagnostic device) will measure binocular ocular functions (bilateral foveal fixation, foveal binocularity, and fovea-tracked saccadic latency) in normal subjects and those with history of mild-to moderate traumatic brain injury (mTBI).

Eligibility

Sex
ALL
Min age
12 Years
Max age
Healthy volunteers
Accepted
Inclusion Criteria: 1. Age 12 years or older at the time of enrollment. 2. Able to understand and sign an informed consent form (or with parent/guardian for subjects less than 18 years of age). 3. Willing and able to complete all required study visits and test assessments. 4. Subjects with no history of traumatic brain injury (normal arm). 5. Subjects with a history of mild to moderate traumatic brain injury (mTBI) within the last six months, (post-TBI arm). Exclusion Criteria: 1. Concurrent participation in another drug or device clinical investigation. 2. Subject with a history of eye disease which could reduce, or limit reflected polarized light from the retina, such as corneal scarring, cataract, glaucoma, degenerative retinal conditions (e.g., age-related macular degeneration, diabetic retinopathy), or other conditions which may decrease device signal reflectance. 3. Subjects who are pregnant, planning to become pregnant, or are breastfeeding.

Primary outcome measure(s)

Trial sites (1)

FacilityCityRegionStatus
Elite Eye Care/Elite Vision Therapy Waukee Iowa Recruiting

More Rebiscan, Inc. trials in the USA

Other trials for the same condition

Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT07742878 on ClinicalTrials.gov ↗ ← All trials in the USA